Gate Bioscience expands Lilly drug deal worth more than $870m

Project to discover medicines designed to eliminate proteins that have been difficult to target

Gate Bioscience expands Lilly drug deal worth more than $870m
Project to discover medicines designed to eliminate proteins that have been difficult to target